Tenaya Therapeutics IncNASDAQ:TNYA
- LAST PRICE4.2000
- TODAY'S CHANGE (%)-0.2800 (-6.2500%)
- Bid / Lots4.2000/ 1
- Ask / Lots4.7200/ 7
- Open / Previous Close4.5400 / 4.4800
- Day Range
- 52 Week Range
- Volume179,517
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TNYA |
|---|---|---|
| 09:32 ET | 783 | 4.54 |
| 09:36 ET | 889 | 4.44 |
| 09:39 ET | 2169 | 4.41 |
| 09:56 ET | 380 | 4.5 |
| 09:59 ET | 195 | 4.48 |
| 10:01 ET | 335 | 4.48 |
| 10:08 ET | 200 | 4.45 |
| 10:10 ET | 100 | 4.45 |
| 10:12 ET | 950 | 4.4 |
| 10:14 ET | 2028 | 4.37 |
| 10:17 ET | 750 | 4.38 |
| 10:33 ET | 150 | 4.3133 |
| 10:35 ET | 107 | 4.308 |
| 10:39 ET | 640 | 4.295 |
| 10:44 ET | 500 | 4.3 |
| 10:53 ET | 3200 | 4.3 |
| 10:55 ET | 1100 | 4.3 |
| 11:02 ET | 2791 | 4.31 |
| 11:06 ET | 346 | 4.33 |
| 11:11 ET | 1795 | 4.34 |
| 11:20 ET | 10300 | 4.271 |
| 11:22 ET | 317 | 4.29 |
| 11:24 ET | 9783 | 4.27 |
| 11:29 ET | 500 | 4.31 |
| 11:33 ET | 700 | 4.3 |
| 11:36 ET | 100 | 4.28 |
| 11:40 ET | 700 | 4.27 |
| 11:47 ET | 800 | 4.26 |
| 11:49 ET | 100 | 4.25 |
| 11:51 ET | 200 | 4.24 |
| 12:03 ET | 1199 | 4.2 |
| 12:05 ET | 1576 | 4.2009 |
| 12:12 ET | 669 | 4.215 |
| 12:14 ET | 300 | 4.2 |
| 12:16 ET | 400 | 4.18 |
| 12:18 ET | 965 | 4.17 |
| 12:20 ET | 200 | 4.2 |
| 12:21 ET | 500 | 4.16 |
| 12:23 ET | 200 | 4.2 |
| 12:27 ET | 100 | 4.2197 |
| 12:30 ET | 2300 | 4.2 |
| 12:36 ET | 200 | 4.2 |
| 12:38 ET | 1000 | 4.1988 |
| 12:39 ET | 200 | 4.2 |
| 12:41 ET | 437 | 4.2251 |
| 12:48 ET | 1130 | 4.23 |
| 12:50 ET | 140 | 4.23 |
| 12:52 ET | 100 | 4.2 |
| 12:57 ET | 100 | 4.22 |
| 12:59 ET | 824 | 4.2 |
| 01:01 ET | 200 | 4.22 |
| 01:03 ET | 100 | 4.2 |
| 01:08 ET | 19569 | 4.2 |
| 01:10 ET | 1050 | 4.19 |
| 01:19 ET | 460 | 4.167 |
| 01:26 ET | 100 | 4.17 |
| 01:32 ET | 100 | 4.16 |
| 01:48 ET | 100 | 4.17 |
| 01:55 ET | 100 | 4.17 |
| 02:02 ET | 1800 | 4.15 |
| 02:08 ET | 130 | 4.15 |
| 02:11 ET | 100 | 4.15 |
| 02:13 ET | 2422 | 4.15 |
| 02:15 ET | 341 | 4.15 |
| 02:18 ET | 100 | 4.145 |
| 02:26 ET | 100 | 4.15 |
| 02:31 ET | 200 | 4.15 |
| 02:40 ET | 300 | 4.16 |
| 02:49 ET | 968 | 4.16 |
| 02:54 ET | 221 | 4.17 |
| 02:56 ET | 522 | 4.17 |
| 03:02 ET | 969 | 4.15 |
| 03:03 ET | 500 | 4.16 |
| 03:05 ET | 200 | 4.1741 |
| 03:09 ET | 1000 | 4.17 |
| 03:12 ET | 927 | 4.1799 |
| 03:14 ET | 682 | 4.18 |
| 03:16 ET | 200 | 4.17 |
| 03:18 ET | 12893 | 4.18 |
| 03:20 ET | 1154 | 4.19 |
| 03:21 ET | 357 | 4.1985 |
| 03:23 ET | 100 | 4.2 |
| 03:25 ET | 942 | 4.195 |
| 03:27 ET | 2200 | 4.2 |
| 03:30 ET | 300 | 4.2 |
| 03:34 ET | 100 | 4.21 |
| 03:36 ET | 200 | 4.22 |
| 03:39 ET | 100 | 4.2 |
| 03:41 ET | 4189 | 4.21 |
| 03:45 ET | 700 | 4.215 |
| 03:52 ET | 3211 | 4.2 |
| 03:54 ET | 6479 | 4.2 |
| 03:56 ET | 2040 | 4.19 |
| 03:57 ET | 3727 | 4.2 |
| 03:59 ET | 1354 | 4.2 |
May 2, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tenaya Therapeutics Inc | 329.8M | -2.5x | --- |
Atea Pharmaceuticals Inc | 327.6M | -2.4x | --- |
Anavex Life Sciences Corp | 322.5M | -7.1x | --- |
Erasca Inc | 320.7M | -2.2x | --- |
Rani Therapeutics Holdings Inc | 318.2M | -4.9x | --- |
Skye Bioscience Inc | 317.7M | -2.0x | --- |
Company Information
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
Contact Information
- Headquarters
- 171 Oyster Point Blvd., Suite 500SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 415-865-2066
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- David Goeddel
- Chief Executive Officer, Director
- Faraz Ali
- Chief Financial and Business Officer
- Leone Patterson
- Chief Scientific Officer
- Timothy Hoey
- Chief Medical Officer
- Whittemore Tingley
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $329.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 78.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.68 |
Book Value | $2.04 |
P/E Ratio | -2.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
